At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients with central nervous system (CNS) disorders.
Our pipeline of product candidates is led by NUPLAZIDTM (pimavanserin), which, if approved, will establish a new and distinctly different pharmacological approach to treating psychosis and be the only drug approved in the United States for the treatment of psychosis associated with Parkinson’s disease. We also are developing pimavanserin for Alzheimer’s disease psychosis and schizophrenia—additional areas with severe unmet medical needs. In addition, we have clinical-stage programs for chronic pain and glaucoma.
Our vision is to become the leading pharmaceutical company dedicated to the advancement of innovative medicines that improve the lives of patients with CNS disorders. Our history is rooted in science and strong leadership in CNS research. We have set ourselves apart by transforming our novel discoveries into important drug candidates that may make a meaningful impact on the lives of patients and the family members who care for them every day.
Parkinson’s disease psychosis, which includes hallucinations and delusions, is frequent and debilitating in people with Parkinson’s disease. We aimed to assess safety and efficacy of pimavanserin, a selective serotonin 5-HT2A inverse agonist, in this population.